Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis.
Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis.
复制标题
糠酸莫米松鼻喷雾剂对常年性过敏性鼻炎患者鼻部症状、生活质量、鼻炎干扰睡眠和鼻一氧化氮的疗效。
DOI：
10.2500/aap.2012.33.3509
复制
发表时间：
2012
影响因子：
2.8
通讯作者：
S. Fujieda
中科院分区：
文献类型：
--
作者：
Takechiyo Yamada;Hideyuki Yamamoto;Seita Kubo;M. Sakashita;Takahiro Tokunaga;D. Susuki;N. Narita;K. Ogi;Masafumi Kanno;Shinji Yamashita;Yuko Terasawa;Y. Kayano;M. Masada;S. Fujieda
鼻腔内皮质类固醇治疗在改善季节性变应性鼻炎的鼻部症状和生活质量(QOL)评分方面显示出有效性。我们前瞻性地研究了呋喃莫米松鼻喷雾剂(MFNS)对常年性变应性鼻炎(PAR)患者的鼻部症状总评分、生活质量评分和睡眠质量的改善作用。同时通过测定鼻腔一氧化氮(NO)来客观评价鼻腔呼吸道状况。57名PAR患者被随机分为MFNS组和安慰剂组，进行为期14天的双盲交叉研究。受试者将他们的症状记录在鼻部症状表和视觉模拟量表上。生活质量和睡眠质量按照日文版的鼻结膜炎生活质量问卷(JRQLQ)和日文版的Epworth嗜睡量表进行调查。用化学发光仪测定鼻腔一次呼气中的NO含量。与安慰剂相比，MFNS治疗显著减少了总的鼻部症状(p<；0.001)。与安慰剂相比，接受MFNS治疗的JRQLQ的日常活动领域(P<；0.005)、户外活动(P<；0.01)、社会功能(P<；0.05)以及总体生活质量评分(P<；0.05)均显著降低。在高度睡眠障碍的MFNS组中，嗜睡程度也显著降低(p<；0.01)。鼻腔NO在MFNS组显著降低(P<；0.005)，尤其是有严重鼻部症状的患者(P<；0.01)。这项前瞻性研究表明，MFNS治疗显著改善了患有PAR的日本患者的鼻部症状、生活质量、睡眠质量和上呼吸道状况。
Intranasal corticosteroid therapy has exhibited effectiveness for improving nasal symptoms and quality of life (QOL) scores associated with seasonal allergic rhinitis. We prospectively investigated the efficacy of mometasone furoate nasal spray (MFNS) for improving the total nasal symptom score, QOL score, and sleep quality in subjects with perennial allergic rhinitis (PAR). Nasal airway conditions were also objectively assessed by measuring nasal nitric oxide (NO). Fifty-seven patients with PAR were randomized to MFNS or placebo for a 14-day, double-blind, crossover study. The subjects recorded their symptoms on nasal symptom forms and a visual analog scale. QOL and sleep quality were surveyed in accordance with the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) and the Japanese version of the Epworth Sleepiness Scale. Nasal NO was measured during a single exhalation using a chemiluminescence analyzer. MFNS treatment achieved significant reductions versus placebo for total nasal symptoms (p < 0.001). There were significant decreases of the usual daily activity domain (p < 0.005), outdoor activities (p < 0.01), social function (p < 0.05), and the overall QOL score (p < 0.05) of JRQLQ with MFNS therapy versus placebo. A significant reduction of the sleepiness scale was also observed in the MFNS group with high sleep disturbance (p < 0.01). A significant decrease of nasal NO was found in the MFNS group (p < 0.01), especially among patients with severe nasal symptoms (p < 0.005). This prospective study indicated that MFNS therapy significantly improves nasal symptoms, QOL, sleep quality, and upper airway condition in Japanese subjects with PAR.